Journey Medical Corp (DERM) Stock Price, Quote & News

Company Profile

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 480 434 6670

Website: journeymedicalcorp.com

Address:

9237 East Via de Ventura Blvd., Suite 105, Scottsdale, United States

Mugu Jun. 25 at 10:04 PM

$DERM major malfunction

0 · Reply

FinSUN Jun. 25 at 8:22 PM

$DERM lol

0 · Reply

Kconn52 Jun. 25 at 8:08 PM

$DERM took advantage of this dip and bought a few thousand shares. I am probably too heavy in this name but I can’t resist what I am certain is a raging bargain.

0 · Reply

Tomasini Jun. 25 at 7:25 PM

$DERM buying op today. got a little out over our skies with no news

0 · Reply

StockBodega Jun. 25 at 4:35 PM

$FBIO $DERM https://finance.yahoo.com/markets/stocks/articles/journey-medical-derm-stock-draws-042922197.html

1 · Reply

hofno2003 Jun. 25 at 1:20 PM

$DERM With Emrosi peak sales of $200M and the revenue of the rest of the pipeline we should get $250 annual revenue. 3 times revenue for calculating the market cap results in about $30/share, with very high net earnings near $2/share, also a (second) justification for a PPS of $30.

0 · Reply

JFais Jun. 24 at 2:04 PM

$DERM - $190M EV. If this were valued at 3x conservative peak sales for Emrosi ($200M), would be a 3x from here

0 · Reply

buymoremakemore Jun. 23 at 9:08 PM

$DERM we are almost back to pre Q4 ER levels.

0 · Reply

gb11 Jun. 22 at 2:51 PM

$DERM why is it rallying all of a sudden? Any news or just shorts covering? A lot of short selling happened last week except during the last hour on thursday where they covered a little bit and today. Anyways I am not complaining.

1 · Reply

buymoremakemore Jun. 22 at 4:52 AM

$DERM $15 - $20 BO. It is not if, it is when. Revenue will be stable with emrosi as insurance coverage improves. A 100M+ stable revenue company will allow an acquirer to earn much more than the 500M - 700M that they’d pay in a BO, since Emrosi patents expire in 2039. Once this gets back to $9, a 60% premium for this company won’t be so crazy. I think Claude and team are packaging this for a BO with moves like securing base business. They dont want to do this for another 5 years. The only thing I worry about is Qbrexza. Patents for that expire throughout next 3-6 years, so a generic could possibly enter in 5 years IMO. That 7M a quarter would be helpful to replace sooner rather than later. The closer Emrosi gets to 100M annual revenue, that won’t matter though. Ex-Us outlicensing for Emrosi would be a game changer, which I have a feeling comes in 2027!

3 · Reply

Journey Medical Transcript: AGM 2026

May 20, 2026, 5:00 PM EDT - 5 weeks ago

Journey Medical Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 19, 2026, 4:45 PM EDT - 5 weeks ago

Market Cap	177.05M
Revenue (ttm)	61.86M
Net Income (ttm)	-11.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	36.74
Profit Margin	-18.48%
Debt to Equity Ratio	0.82

Volume	439,400
Avg Vol	244,922
Day's Range	N/A - N/A
Shares Out	27.54M
Stochastic %K	76%
Beta	1.09
Analysts	Strong Sell
Price Target	$13.50